异动解读 | STRUCTURE THERAPEUTICS INC盘中大涨7.98%,多家券商给予买入评级

异动解读
09 Dec 2024

STRUCTURE THERAPEUTICS INC (GPCR.us)今日盘中大涨7.98%,股价涨幅引发了市场关注。

从公司基本面看,STRUCTURE THERAPEUTICS INC是一家临床阶段的生物制药公司,主要开发治疗糖尿病、肥胖症等慢性病的候选药物。该公司主打产品GSBR-1290是一种G蛋白偶联受体(GPCR)小分子激动剂,有望成为2型糖尿病和肥胖症新型口服治疗方案。

另外,据最新财报数据显示,该公司虽然目前处于研发投入期暂无营收,但机构对其发展前景仍然持看好态度。目前有100%的参与评级机构给予该股买入评级,并无任何卖出或持有评级。这可能是推动其股价上涨的重要原因之一。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10